Back to results

A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients (VANCE)

Primary Purpose

Nasopharyngeal Carcinoma

Status

Completed

Phase

Phase 3

Locations

International

Study Type

Interventional

Intervention

autologous EBV specific Cytotoxic T cells

combination IV gemcitabine and IV carboplatin (AUC2)

About this trial

This is an interventional treatment trial for Nasopharyngeal Carcinoma focused on measuring Nasopharyngeal Carcinoma (NPC), NPC, immunotherapy, Nasopharyngeal Cancer, Nose Cancer, Cell therapy, Head and Neck Cancer, Cytotoxic T cells, chemotherapy, Epstein-Barr Virus

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria

Metastatic or locally recurrent EBV-positive, non-keratinizing and/ or undifferentiated NPC* who do not have curative options such as chemo-radiation or surgery
*Subjects will be enrolled based on confirmed histology diagnosis of the NPC
Radiologically measurable disease as per RECIST 1.1
Human Immunodeficiency Virus (HIV) negative*
* Status of HIV must be confirmed via a HIV antibody test or other confirmatory tests available within 4 weeks of screening
Bilirubin <2 x upper limit of normal (ULN) and aspartate aminotransferase (AST), alanine aminotransferase (ALT) <3 x ULN
Calculated creatinine clearance (CRCL) ≥40 mL/min. Glomerular Filtration Rate (GFR) is calculated based on Cockcroft-Gault method.
Normal corrected calcium levels
Absolute neutrophil count >1200/mm3, hemoglobin (Hb) ≥10 g/dL and platelets ≥100,000/mm3
Male or female
Age ≥ 18 years or according to local legal age of consent
Eastern Cooperative Oncology Group Performance Scale (ECOG-PS) ≤2
Written informed consent
Life expectancy >6 months

Key Exclusion Criteria

Severe concomitant illness i.e. chronic obstructive pulmonary disease (COPD), ischemic heart disease (IHD), active congestive cardiac failure (CCF), active angina pectoris, uncontrolled arrhythmia, uncontrolled hypertension
HIV Positive*
* Status of HIV must be confirmed via a HIV antibody test or other confirmatory tests available within 4 weeks of screening
Pregnant or lactating females
Refuse of use of contraception during trial (both male and female patients)
Investigational therapy less than one month prior to study entry
Pre-existing peripheral neuropathy (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] ≥2)
Central nervous system metastasis
Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study, EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis and T1] or any cancer curatively treated >3 years prior to study entry
Positive hepatitis B surface antigen (HBsAg) results
Known history of hepatitis C and recovery status has not been determined at time of screening
Prior anti-cancer treatment for metastatic or locally recurrent disease, EXCEPT:
For metastatic or locally recurrent disease, localised palliative radiotherapy is allowed.
For locally recurrent disease, the following treatment is allowed
- Prior radiotherapy with curative intent
- Prior chemo-radiotherapy with curative intent
- Adjuvant chemotherapy
- Localised palliative radiotherapy Prior chemotherapy must be > 6 months before screening
Severe intercurrent infections
Prior immunotherapy for metastatic or locally recurrent disease

The following is allowable:

• Adjuvant immunotherapy/ biologics Prior adjuvant immunotherapy/ biologics must be > 6 months before screening

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Arm A

Arm B

Arm Description

4 cycles* of combination IV Gemcitabine (1000 mg/m2) and IV carboplatin (AUC2) on Days 1, 8, 15 every 28 days, followed sequentially by T-cell immunotherapy (2 cycles) of autologous EBV specific Cytotoxic T cells every 2 weeks, followed by EBV-specific CTL immunotherapy (4 cycles) every 8 weeks after 6 weeks from the second cycle. *Additional 1-2 chemotherapy cycles (up to total 6 chemo cycles) might be given upon discretion of Investigator, if EBV-specific CTL infusions are not available in time for the 1st scheduled infusion. As of 1 May 2020, patients who have not received the first infusion of EBV-specific CTLs, will instead continue to receive a total of 6 cycles combination of Gemcitabine (1000 mg/m2) and carboplatin (AUC2) on Days 1, 8, 15 every 28 days

6 cycles of combination IV gemcitabine (1000 mg/m2) and IV carboplatin (AUC2) on Days 1, 8, 15 every 28 days.

Outcomes

Primary Outcome Measures

Overall Survival (OS) of Subjects With Advanced Nasopharyngeal Carcinoma.

Efficacy of EBV-CTL following first line chemotherapy was compared to chemotherapy alone in terms of OS of subjects with advanced nasopharyngeal carcinoma. Overall survival was defined as the duration in months from the day of randomization until death from any cause for a subject known to be deceased, or censored at the last contact date that a subject was known to be alive or lost to follow-up.

Secondary Outcome Measures

Progression-free Survival (PFS) of Subjects With Advanced Nasopharyngeal Carcinoma.

Progression-free survival was defined as the duration from randomization to the first occurrence of documented disease progression [based on imaging results] or death from any cause, whichever occurred first.

Overall Response Rate (ORR) of Subjects With Advanced Nasopharyngeal Carcinoma.

Overall response rate was assessed by sites using computed tomography/magnetic resonance imaging based on RECIST version 1.1, which defined Complete Response (CR) as disappearance of all lesions and pathologic lymph nodes; Partial Response (PR) as >=30% decrease in the sum of the longest diameter (SLD) of target lesions, no new lesions, no progression of non-target lesions; Stable disease (SD) as no PR and no progressive disease (PD); PD as >=20% increase SLD compared to smallest SLD or progression of non-target lesions or new lesions. The ORR for each treatment arm was comprised of the proportion of subjects who achieved a best overall response of CR or PR while on treatment (until End of Treatment visit), taking as reference the tumor measurement at baseline. Subjects who achieved CR or PR are responders, otherwise are non-responders.

Clinical Benefit Rate (CBR) of Subjects With Advanced Nasopharyngeal Carcinoma.

Clinical benefit rate (CBR) was assessed using computed tomography/magnetic resonance imaging based on RECIST version 1.1., which defined CR as disappearance of all lesions and pathologic lymph nodes; PR as >=30% decrease in the sum of the longest diameter (SLD) of target lesions, no new lesions, no progression of non-target lesions; SD as no PR and no PD; PD as >=20% increase SLD compared to smallest SLD or progression of non-target lesions or new lesions. CBR was defined as the proportion of subjects who achieved CR, PR, or SD while on treatment (until End of Treatment visit), taking as reference the tumor measurement at baseline.

Best Overall Response (BOR) of Subjects With Advanced Nasopharyngeal Carcinoma.

Best overall response (BOR) was assessed using computed tomography/magnetic resonance imaging based on RECIST version 1.1., which defined CR as disappearance of all lesions and pathologic lymph nodes; PR as >=30% decrease in the sum of the longest diameter (SLD) of target lesions, no new lesions, no progression of non-target lesions; SD as no PR and no PD; PD as >=20% increase SLD compared to smallest SLD or progression of non-target lesions or new lesions. The BOR of each treatment arm consisted of CR, PR, SD, PD, NE, and NA while on treatment (until End of Treatment visit), taking as reference the tumor measurement at baseline. The ORR was comprised of the proportion of subjects who achieved a BOR of CR or PR.

Full Information

NCT ID

NCT02578641

First Posted

October 12, 2015

Last Updated

June 7, 2023

Sponsor

Tessa Therapeutics

1. Study Identification

Unique Protocol Identification Number

NCT02578641

Brief Title

A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients

Acronym

VANCE

Official Title

A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma(NPC) Patients

Study Type

Interventional

2. Study Status

Record Verification Date

June 2023

Overall Recruitment Status

Completed

Study Start Date

July 2014 (Actual)

Primary Completion Date

February 28, 2022 (Actual)

Study Completion Date

February 28, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Tessa Therapeutics

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

This study is a multi-center, randomized, open label, Phase III clinical trial for advanced Nasopharyngeal Carcinoma(NPC) Patients. Drugs used in chemotherapy, such as gemcitabine and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving an infusion of a person's cytotoxic T cells (CTL) that have been treated in the laboratory may help the body build an effective immune response to kill tumor cells. Giving combination chemotherapy together with laboratory-treated T cells may kill more tumor cells. This Phase III trial is to assess if combined gemcitabine-carboplatin (GC) followed by adoptive T-cell therapy would improve clinical outcome for patients with advanced nasopharyngeal carcinoma (NPC). It is also the world's first, and largest, Phase 3 T-cell therapy cancer trial ever conducted, and enrollment is ongoing for 330 patients from 30 hospital centers across Asia and the United States. This clinical trial is conducted on the back of a successful Phase 2 NPC trial involving 38 patients at the National Cancer Centre, Singapore. This trial produced the best published 2-year (62.9%), and median overall survival (OS) data (29.9 months) in 35 patients with advanced NPC who received autologous EBV-specific CTL. Kindly see https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978790/ for the Phase 2 publication titled "Adoptive T-cell Transfer and Chemotherapy in the First line treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma".

Detailed Description

330 patients will be randomized after their eligibility status has been fully determined and informed consent has been obtained. Patients will be randomly allocated to receive either Arm A (Gemcitabine and Carboplatin (GC) x 4* cycles and EBV-specific CTL) or Arm B (GC x 6 cycles alone) in a 1:1 ratio using a stratified block randomization scheme. The stratification variables are country and disease stage (metastatic vs locally recurrent). *Additional 1-2 chemotherapy cycles (up to total 6 chemo cycles) might be given upon discretion of Investigator, if EBV-specific CTL infusions are not available in time for the 1st scheduled infusion. After randomization, patients in Arm A will have their peripheral blood taken for the establishment of cytotoxic T cell line and EBV transformed lymphoblastoid cell line (CTL). Within two weeks of enrollment, patients will commence combination GC chemotherapy for a total of 4 cycles. Patients in Stage 2 of study will receive the EBV-specific CTL immunotherapy. As of 1 May 2020, patients who have not received the first infusion of EBV-specific CTLs, will instead continue to receive a total of 6 cycles combination of Gemcitabine (1000 mg/m2) and carboplatin (AUC2) on Days 1, 8, 15 every 28 days

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Nasopharyngeal Carcinoma

Keywords

Nasopharyngeal Carcinoma (NPC), NPC, immunotherapy, Nasopharyngeal Cancer, Nose Cancer, Cell therapy, Head and Neck Cancer, Cytotoxic T cells, chemotherapy, Epstein-Barr Virus

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 3

Interventional Study Model

Parallel Assignment

Masking

None (Open Label)

Allocation

Randomized

Enrollment

330 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Arm A

Arm Type

Experimental

Arm Description

Arm Title

Arm B

Arm Type

Active Comparator

Arm Description

6 cycles of combination IV gemcitabine (1000 mg/m2) and IV carboplatin (AUC2) on Days 1, 8, 15 every 28 days.

Intervention Type

Biological

Intervention Name(s)

autologous EBV specific Cytotoxic T cells

Intervention Description

The CTL line will be prepared by co-cultivation of the irradiated EBV-LCL with patient PBMC. A proportion of peripheral blood will be used to generate EBV specific CTLs.

Intervention Type

Drug

Intervention Name(s)

combination IV gemcitabine and IV carboplatin (AUC2)

Intervention Description

4 cycles for Arm A and 6 cycles for Arm B

Primary Outcome Measure Information:

Title

Overall Survival (OS) of Subjects With Advanced Nasopharyngeal Carcinoma.

Description

Time Frame

From randomization until death, assessed up to 7 years. Survivors and lost to follow-up subjects were censored at the date of last contact. Survival follow-up was done every 12 weeks from end of treatment.

Secondary Outcome Measure Information:

Title

Progression-free Survival (PFS) of Subjects With Advanced Nasopharyngeal Carcinoma.

Description

Time Frame

From randomization until first occurrence of disease progression or death of any cause, whichever occurred first, assessed up to 7 years. Subjects who received subsequent anti-cancer therapy were censored at the date of last tumor assessment.

Title

Overall Response Rate (ORR) of Subjects With Advanced Nasopharyngeal Carcinoma.

Description

Time Frame

From randomization until End of Treatment, an average of 13 months for the gemcitabine+carboplatin and EBVCTL arm and 6 months for the gemcitabine+carboplatin only arm.

Title

Clinical Benefit Rate (CBR) of Subjects With Advanced Nasopharyngeal Carcinoma.

Description

Time Frame

From randomization until End of Treatment, an average of 13 months for the gemcitabine+carboplatin and EBVCTL arm and 6 months for the gemcitabine+carboplatin only arm.

Title

Best Overall Response (BOR) of Subjects With Advanced Nasopharyngeal Carcinoma.

Description

Time Frame

From randomization until End of Treatment, an average of 13 months for the gemcitabine+carboplatin and EBVCTL arm and 6 months for the gemcitabine+carboplatin only arm.

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Key Inclusion Criteria Metastatic or locally recurrent EBV-positive, non-keratinizing and/ or undifferentiated NPC* who do not have curative options such as chemo-radiation or surgery *Subjects will be enrolled based on confirmed histology diagnosis of the NPC Radiologically measurable disease as per RECIST 1.1 Human Immunodeficiency Virus (HIV) negative* * Status of HIV must be confirmed via a HIV antibody test or other confirmatory tests available within 4 weeks of screening Bilirubin <2 x upper limit of normal (ULN) and aspartate aminotransferase (AST), alanine aminotransferase (ALT) <3 x ULN Calculated creatinine clearance (CRCL) ≥40 mL/min. Glomerular Filtration Rate (GFR) is calculated based on Cockcroft-Gault method. Normal corrected calcium levels Absolute neutrophil count >1200/mm3, hemoglobin (Hb) ≥10 g/dL and platelets ≥100,000/mm3 Male or female Age ≥ 18 years or according to local legal age of consent Eastern Cooperative Oncology Group Performance Scale (ECOG-PS) ≤2 Written informed consent Life expectancy >6 months Key Exclusion Criteria Severe concomitant illness i.e. chronic obstructive pulmonary disease (COPD), ischemic heart disease (IHD), active congestive cardiac failure (CCF), active angina pectoris, uncontrolled arrhythmia, uncontrolled hypertension HIV Positive* * Status of HIV must be confirmed via a HIV antibody test or other confirmatory tests available within 4 weeks of screening Pregnant or lactating females Refuse of use of contraception during trial (both male and female patients) Investigational therapy less than one month prior to study entry Pre-existing peripheral neuropathy (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] ≥2) Central nervous system metastasis Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study, EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis and T1] or any cancer curatively treated >3 years prior to study entry Positive hepatitis B surface antigen (HBsAg) results Known history of hepatitis C and recovery status has not been determined at time of screening Prior anti-cancer treatment for metastatic or locally recurrent disease, EXCEPT: For metastatic or locally recurrent disease, localised palliative radiotherapy is allowed. For locally recurrent disease, the following treatment is allowed Prior radiotherapy with curative intent Prior chemo-radiotherapy with curative intent Adjuvant chemotherapy Localised palliative radiotherapy Prior chemotherapy must be > 6 months before screening Severe intercurrent infections Prior immunotherapy for metastatic or locally recurrent disease The following is allowable: • Adjuvant immunotherapy/ biologics Prior adjuvant immunotherapy/ biologics must be > 6 months before screening

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Han Chong TOH

Organizational Affiliation

National Cancer Centre Singapore (NCCS)

Official's Role

Study Chair

Facility Information:

Facility Name

City of Hope National Medical Center

City

Duarte

State/Province

California

ZIP/Postal Code

91010

Country

United States

Facility Name

University of California Davis Health

City

Sacramento

State/Province

California

ZIP/Postal Code

95817

Country

United States

Facility Name

UCSF HDF Comprehensive Cancer Center

City

San Francisco

State/Province

California

ZIP/Postal Code

94143

Country

United States

Facility Name

Stanford Cancer Center

City

Stanford

State/Province

California

ZIP/Postal Code

94305

Country

United States

Facility Name

Massachusetts General Hospital

City

Boston

State/Province

Massachusetts

ZIP/Postal Code

02215

Country

United States

Facility Name

Baylor Scott & White

City

Dallas

State/Province

Texas

ZIP/Postal Code

75204

Country

United States

Facility Name

Baylor College of Medicine

City

Houston

State/Province

Texas

ZIP/Postal Code

77030

Country

United States

Facility Name

Site MY-03

City

George Town

State/Province

Penang

Country

Malaysia

Facility Name

Site MY-06

City

George Town

State/Province

Penang

Country

Malaysia

Facility Name

Site MY-07

City

Johor Bahru

Country

Malaysia

Facility Name

Site MY-01

City

Kuala Lumpur

Country

Malaysia

Facility Name

Site MY-04

City

Kuala Lumpur

Country

Malaysia

Facility Name

Site MY-05

City

Kuala Lumpur

Country

Malaysia

Facility Name

Site MY-08

City

Kuala Lumpur

Country

Malaysia

Facility Name

Site SG-11

City

Singapore

Country

Singapore

Facility Name

Site SG-12

City

Singapore

Country

Singapore

Facility Name

Changhua Christian Hospital

City

Changhua

Country

Taiwan

Facility Name

Kaohsiung Chang Gung Memorial Hospital

City

Kaohsiung

Country

Taiwan

Facility Name

China Medical University Hospital

City

Taichung

Country

Taiwan

Facility Name

Taichung Veterans General Hospital

City

Taichung

Country

Taiwan

Facility Name

National Taiwan University Hospital

City

Taipei

Country

Taiwan

Facility Name

Taipei Veterans General Hospital

City

Taipei

Country

Taiwan

Facility Name

Linkou Chang Gung Memorial Hospital

City

Taoyuan

Country

Taiwan

Facility Name

Site TH-42

City

Bangkok

Country

Thailand

Facility Name

Site TH-43

City

Bangkok

Country

Thailand

Facility Name

Site TH-41

City

Chiang Mai

Country

Thailand

Facility Name

Site TH-44

City

Khon Kaen

Country

Thailand

Facility Name

Site TH-47

City

Lopburi

Country

Thailand

Facility Name

Site TH-45

City

Ubon Ratchathani

Country

Thailand

Facility Name

Site TH-46

City

Udon Thani

Country

Thailand

12. IPD Sharing Statement

Links:

URL

http://www.tessatherapeutics.com/

Description

Sponsor

Learn more about this trial

A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients

We'll reach out to this number within 24 hrs

A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients (VANCE)

Nasopharyngeal Carcinoma

About this trial

Eligibility Criteria

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

1. Study Identification

2. Study Status

3. Sponsor/Collaborators

4. Oversight

5. Study Description

6. Conditions and Keywords

7. Study Design

8. Arms, Groups, and Interventions

10. Eligibility

12. IPD Sharing Statement

Learn more about this trial